Hot Biotechs (fka HOTBIO)

[BioSpecialist]

THIS IS THE NEXT BIG MONSTER STOCK ..READ WHY

This is a real unknown gem ,once investors discover this stock it will explode like a nuclear bomb .LOAD UP THE TRUCK WHILE YOU STILL CAN BECAUSE ITS TRADING SIGNIFCANTLY BELOW CASH LEVEL !!

NDA filing for Blockbuster Marqibo next quarter and it could be approved before the end of this Year .

MARKET CAP OF 10 MILLION MAKES ME A BIG LAUGH // TLON WILL MOVE INTO DOUBLE DIGITS IN THE COMING MONTHS (As an example 10$ per share means 270 Mil Market Cap even at 10$ A BIG JOKE !!

Talon Therapeutics (TLON.OB)

Market Cap: $10,4 Mil
Cash: 27,2 Mil
Price : 0.48 $

Shares Out: 21,2 Mil


New Presentation // A MUST READ !!
http://www.talontx.com/pdf/talontx_corp_pres.pdf

Marqibo® is poised for accelerated approval in 4Q 2011
NDA submission and request for priority revue expected in 2Q 2011
Sought indica<on =Adult Ph(--)ALL in 2nd relapse or that has failed 2lines of Rx
35% overall response rate as 3rd-­6th line treatment in RALLY study
20% complete response rate with impressive median dura<on and survival

.................

http://biotuesdays.com/2011/02/01/talon-to-seek-accelerated-approval-of-marqibo/

Talon Therapeutics (OTCBB:TLON) plans to submit a new drug application with the FDA for priority review of its Marqibo oncology drug in the second quarter this year and is hoping for accelerated approval in the final quarter of the year.

“We are seeking accelerated approval based on data from our Phase 2 RALLY study where we demonstrated a 35% overall response rate using single agent Marqibo as third, fourth, fifth or sixth line treatment,” CEO Dr. Steven Deitcher says in an exclusive interview with BioTuesdays.com. “This is the most heavily pretreated and advanced Acute Lymphoblastic Leukemia (ALL) population that has ever been described or studied in the literature.”

If Marqibo is cleared by the FDA for use in additional, larger indications, Talon is looking at a multibillion-dollar potential